Abstract Number: 2095 • 2015 ACR/ARHP Annual Meeting
Dietary Patterns (DASH, Prudent, Western Diets) and the Risk of Gout in US Women – the Nurses Health Study
Background/Purpose: There is a remarkable, rising disease burden of gout and associated cardiovascular-metabolic comorbidities (e.g., hypertension in 74% and obesity in 53% of cases in…Abstract Number: 2099 • 2015 ACR/ARHP Annual Meeting
Genome-Wide Association Study of Clinically-Defined Gout Identifies Multiple Risk Loci: A Clue for Future Companion Diagnostics of Gout
Background/Purpose: Gout, caused by hyperuricaemia, is a multifactorial disease. Recently, genome-wide association studies (GWASs) of gout have been reported; however, they included self-reported gout cases.…Abstract Number: 2108 • 2015 ACR/ARHP Annual Meeting
A Pragmatic Cluster-Randomized Controlled Trial of an Automated, Pharmacy-Based Intervention to Optimize Allopurinol Therapy in Gout
Background/Purpose: Gout is a common form of inflammatory arthritis, often treated with allopurinol as a first-line urate lowering therapy. We have designed a large…Abstract Number: 2110 • 2015 ACR/ARHP Annual Meeting
Imaging and Safety Assessments Following Treatment with Febuxostat and Placebo for 2 Years in Subjects with Early Gout
Background/Purpose: No clinical trials had previously investigated the characteristics of joint damage in early gout or the benefit of instituting urate-lowering therapy (ULT) earlier in…Abstract Number: 2111 • 2015 ACR/ARHP Annual Meeting
A Study to Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients
Background/Purpose: Arhalofenate is a novel Urate-Lowering Anti-Flare Therapy (ULAFT) to treat gout. It lowers serum uric acid (sUA) by blocking URAT1, a tubular UA transporter, and…Abstract Number: 2112 • 2015 ACR/ARHP Annual Meeting
Analysis of Gout Subjects Receiving Lesinurad and Allopurinol Combination Therapy By Baseline Renal Function
Background/Purpose: Two randomized, double-blind, placebo-controlled Phase III clinical trials showed that lesinurad (200 or 400 mg) when added to allopurinol (200-900 mg) significantly increased the…Abstract Number: 2113 • 2015 ACR/ARHP Annual Meeting
Lesinurad, a Novel Selective Uric Acid Reabsorption Inhibitor, in Combination with Febuxostat, in Patients with Tophaceous Gout
Background/Purpose: Lesinurad (LESU; RDEA594) is a selective uric acid reabsorption inhibitor (SURI) being investigated for the treatment of gout in combination with a xanthine oxidase…Abstract Number: 2228 • 2015 ACR/ARHP Annual Meeting
Brief Educational Intervention Improves Gout Patients’ Understanding of Their Disease
Background/Purpose: To assess gout patients’ baseline knowledge of their disease and to measure knowledge improvement after brief educational session. Methods: In this study, 13 patients…Abstract Number: 2239 • 2015 ACR/ARHP Annual Meeting
Prevalence of Gout and Hyperuricemia and Association with Fat Mass and Fat Free Mass: Results from a Population-Based Study
Background/Purpose: Gout and hyperuricemia are major co-morbid health issues worldwide, with a known association with metabolic syndrome. Only one previous study based in Vietnam, has…Abstract Number: 2241 • 2015 ACR/ARHP Annual Meeting
Treating to Target in Gout: The Epidemiology of Serum Urate Measurement Among Patients with Incident Gout in Usual Care Settings in the United States
Background/Purpose: American College of Rheumatology (ACR) guidelines recommend lowering serum urate (sUA) to a target value in patients with gout to prevent crystal deposition/promote crystal…Abstract Number: 2242 • 2015 ACR/ARHP Annual Meeting
Compliance with Allopurinol Among Hypertensive Patients with Gout Diagnosis and the Relationship to Onset of End-Stage Renal Disease
Background/Purpose: The risk of end-stage renal disease (ESRD) in both hypertension and gout has been examined in the clinical literature. However, the impact of allopurinol…Abstract Number: 2243 • 2015 ACR/ARHP Annual Meeting
Economic Burden of Controlled Gout, Uncontrolled Gout, and Gout Exacerbated By Common Comorbidities: Results from the 2012-2013 National Health and Wellness Survey
Background/Purpose: Gout is one of the most common forms of inflammatory arthritis and is caused by chronic high serum uric acid (sUA) levels (ie, hyperuricemia),…Abstract Number: 2244 • 2015 ACR/ARHP Annual Meeting
Risk of Incident Atrial Fibrillation in Gout
Background/Purpose: Atrial fibrillation (AF) is the most common arrhythmia associated with cardiovascular disease and mortality. There are increasing data supporting the role of inflammation in…Abstract Number: 2341 • 2015 ACR/ARHP Annual Meeting
Treatment of Gout with Pharmacological Vs. Non-Pharmacological Complementary Therapy in the U.S.: An Internet Survey
Background/Purpose: The interplay of use of dietary supplement, diet modification and ULT adherence in gout management is not known. Therefore, we aimed to begin to…Abstract Number: 2344 • 2015 ACR/ARHP Annual Meeting
A 3-Year Follow-up Study of Canakinumab in Frequently Flaring Gouty Arthritis Patients, Contraindicated, Intolerant, or Unresponsive to Nonsteroidal Anti-Inflammatory Drugs and/or Colchicine
Background/Purpose: Although anti-inflammatory drugs such as nonsteroidal anti-inflammatory drugs and colchicine are the recommended treatment options for pain and inflammation management in patients (pts) with…
Simple Search Results
Didn't find what you were looking for? Try the Advanced Search »
Didn't find what you were looking for? Try the Advanced Search »